PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.47%
Both yoy net incomes decline, with TRVN at -20.74%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-1.12%
Negative yoy D&A while TRVN is 7.36%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
11.01%
Some yoy growth while TRVN is negative at -38.24%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
20.13%
SBC growth well above TRVN's 6.42%. Michael Burry would flag major dilution risk vs. competitor’s approach.
171.56%
Well above TRVN's 99.15% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.25%
AP growth of 36.25% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
60.10%
Some yoy usage while TRVN is negative at -123.91%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
20.13%
Some yoy increase while TRVN is negative at -2.41%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
23.86%
Some CFO growth while TRVN is negative at -12.42%. John Neff would note a short-term liquidity lead over the competitor.
-1272.99%
Both yoy lines negative, with TRVN at -4003.63%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1272.99%
Both yoy lines negative, with TRVN at -42.93%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-196.64%
We cut debt repayment yoy while TRVN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1193.74%
Lower share issuance yoy vs. TRVN's 2028360.20%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.